Texas A&M spin-off, Pulmotect, Inc., receives $3 million NIH grant to fund infection prevention drug trials
Clinical-stage biotechnology company Pulmotect, Inc., has been awarded a $3 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to evaluate the safety and effectiveness of PUL-042, an inhaled therapeutic designed to prevent and treat respiratory infections in cancer patients with compromised immune systems.
International collaboration and innovative partnerships with industry, government, speeding bench-to-bedside discoveries
Whether it’s an inhaled therapeutic that stimulates innate immunity of the lungs to prevent the spread of bacterial and viral infections, or a novel tuberculosis test that allows doctors to diagnose the infectious disease within minutes, the partnerships between academic institutions, their spinoff companies, industry, and government are the driving force behind advancing these products to the market — and on faster timelines than ever before.
Biomedical research should ultimately benefit patients. That’s the driving force behind the work being done by LauraLee Hughes and her staff in the Texas A&M Health Science Center’s Office of Technology Translation (OTT).